Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study aimed to analyze the safety of 90-min intravenous rapid infusion of obinutuzumab
in patients with B-cell non-Hodgkin's lymphoma and to provide evidence for the applicability
of rapid infusion regimens in chemotherapy in China.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University